Mineralys Therapeutics Files 8-K

TL;DR

Mineralys Therapeutics filed an 8-K on Sept 3, 2025, covering other events and financials.

AI Summary

Mineralys Therapeutics, Inc. filed an 8-K on September 3, 2025, reporting other events and financial statements. The filing details the company's incorporation in Delaware, its principal executive offices in Radnor, Pennsylvania, and its standard industrial classification in Pharmaceutical Preparations.

Why It Matters

This 8-K filing serves as an official record of corporate events and financial disclosures for Mineralys Therapeutics, Inc., providing transparency to investors and the public.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Numbers

• 001-41614 — SEC File Number (Identifies the company's filing with the SEC.)
• 84-1966887 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• Mineralys Therapeutics, Inc. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Radnor, Pennsylvania (location) — Principal executive offices
• September 2, 2025 (date) — Date of earliest event reported
• September 3, 2025 (date) — Date of report

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share MLYS The Nasdaq Stock Mark
• $25.50 — price to the public in this offering is $25.50 per share. The Underwriters have agreed
• $23.97 — he Underwriting Agreement at a price of $23.97 per share. The net proceeds to the Comp
• $234.7 m — fering are expected to be approximately $234.7 million, or approximately $269.9 million
• $269.9 million — mately $234.7 million, or approximately $269.9 million if the Underwriters' option to purchase

Filing Documents

• mlys-20250902.htm (8-K) — 34KB
• exhibit11-8xkseptember2025.htm (EX-1.1) — 258KB
• exhibit51-8xkseptember2025.htm (EX-5.1) — 21KB
• exhibit991-8xkseptember2025.htm (EX-99.1) — 11KB
• exhibit992-8xkseptember2025.htm (EX-99.2) — 10KB
• image_0.jpg (GRAPHIC) — 9KB
• logo.jpg (GRAPHIC) — 10KB
• lwlogoa.jpg (GRAPHIC) — 102KB
• 0001933414-25-000120.txt ( ) — 691KB
• mlys-20250902.xsd (EX-101.SCH) — 2KB
• mlys-20250902_lab.xml (EX-101.LAB) — 23KB
• mlys-20250902_pre.xml (EX-101.PRE) — 13KB
• mlys-20250902_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On September 2, 2025, Mineralys Therapeutics, Inc. ("Mineralys" or the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC as representatives of the several underwriters named therein (collectively, the "Underwriters"), relating to the issuance and sale of 9,803,921 shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"). The price to the public in this offering is $25.50 per share. The Underwriters have agreed to purchase the shares from the Company pursuant to the Underwriting Agreement at a price of $23.97 per share. The net proceeds to the Company from this offering are expected to be approximately $234.7 million, or approximately $269.9 million if the Underwriters' option to purchase additional shares is exercised in full, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. In addition, under the terms of the Underwriting Agreement, the Company has granted the Underwriters a 30-day option to purchase up to 1,470,588 additional shares of Common Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on September 4, 2025, subject to the satisfaction of customary closing conditions. The offering is being made pursuant to the Company's registration statements on Form S-3 and Form S-3MEF (Registration Statement Nos. 333-278122 and 333-289998, respectively) previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"), and a prospectus supplement and accompanying prospectus filed with the SEC. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, a

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated September 2, 2025, by and among Mineralys Therapeutics, Inc. and BofA Securities, Inc., Evercore Group L.L.C. and Goldman Sachs & Co. LLC, as representatives of the several underwriters named therein 5.1 Opinion of Latham & Watkins LLP 23.1 Consent of Latham & Watkins LLP (included in Exhibit 5.1) 99.1 Press Release dated September 2, 2025 99.2 Press Release dated September 2, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MINERALYS THERAPEUTICS, INC. Date: September 3, 2025 By: /s/ Adam Levy Name: Adam Levy Title: Chief Financial Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR